Karbinal ER (Carbinoxamine Maleate) Patent Expiration, LOE Window & CMS Spending

Karbinal ER (Carbinoxamine Maleate) by Aytu: FDA Orange Book LOE 2029-03-29, 2 AB generics, $1.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAytu
FDA Application & PathwayN022556 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-03-29
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$1.9M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$1.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel